Eliana Clark has sold NTLA and made no open-market buys since Jan 2023

Eliana Clark, PhD, is the Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc. (NTLA), where she oversees technical operations, quality, process development, and manufacturing for the company's CRISPR-based gene editing therapies.( She previously served as Senior Vice President of Technical Operations and Quality at Intellia, and before that held senior roles in product and portfolio management, manufacturing sciences, process development, and CMC-regulatory at Biogen and Sanofi/Genzyme.(

With over 35 years of experience in biopharmaceutical process, analytical, and technology development, as well as regulatory and supply chain operations, Clark brings extensive expertise to her role.( Prior to industry, she was a professor in the Chemical and Biological Engineering Department at Tufts University for nearly 15 years, and held postdoctoral positions in Biochemical Engineering at the University of Delaware and Worcester Polytechnic Institute.( She earned a PhD and Bachelor of Engineering in Chemical Engineering from Universidad Nacional del Litoral in Santa Fe, Argentina, and completed the Greater Boston Executive Program at MIT Sloan.(

Written by Perplexity from public sources.